Document is current

Article History

Received: 24 March 2025

Accepted: 1 August 2025

First Online: 19 August 2025

Declarations

:

: In the last three years SL has received honoraria for advising/consulting and/or for lectures and/or for educational material from Angelini, Apsen, Boehringer Ingelheim, Eisai, Ekademia, GedeonRichter, Janssen, Karuna, Kynexis, Lundbeck, Medichem, Medscape, Mitsubishi, Neurotorium, Otsuka, NovoNordisk, Recordati, Rovi, Teva. AH is editor of the German (DGPPN) schizophrenia treatment guidelines, first author of the WFSBP schizophrenia treatment guidelines; on advisory boards of and speaker fees from AbbVie, Advanz (speaker fees only), Janssen-Cilag, Lundbeck, Recordati, Rovi, Teva, and Otsuka. KB has received honoraria for advising/consulting and/or for lectures and/or for educational material from Böhringer Ingelheim and Angelini. KB is a co-founder of the digital healthcare start-ups KISO Health and MentalHub. MZ has received honoraria for lectures or advisory activities from Boehringer-Ingelheim. PF has received research support or honoraria for lectures or advisory activities from Boehringer-Ingelheim, Janssen, Lundbeck, Otsuka, Recordati and Richter. IM has received speaker fees from Boehringer Ingelheim. SS, EB and KU are employees and/or shareholders of Mindpax.me.

: The study was approved by the review board of the Ethics Committee of the Technical University of Munich (approval number 2024-242-S-KK). The responsible ethics committees for the participating clinics have followed this vote accordingly. This scientific study aims to examine whether smartphone-based symptom monitoring triggers positive effects on patient-relevant outcomes. The smartphone app is not intended to be further developed as a medical product or to pursue a commercial interest.

: Patients meeting inclusion criteria are asked to provide informed consent (template of the informed consent form available upon request) for study participation, and their capability to provide informed consent is ensured by trained study staff. Consent can be withdrawn at any time, without giving reasons and without disadvantages for further medical care. Should the study be terminated by the clinician or patient, the data stored up to this point will continue to be used unless the patient or caregiver explicitly withdraws the release of their patient data. In the event of withdrawal of consent, the stored data will be destroyed at the patient’s request. Data is saved and exchanged exclusively in pseudonymized forms. The pseudonyms represent patient´s affiliations with the respective outpatient clinic and do not include any identifying information such as date of birth or initials. The names of the patients and all other confidential information are subject to medical confidentiality and the provisions of the Federal Data Protection Act. The consent form and personal data remain in the recruiting center.